Clene (NASDAQ:CLNN) Stock Rating Reaffirmed by Benchmark

Benchmark reissued their buy rating on shares of Clene (NASDAQ:CLNN – Free Report) in a report issued on Thursday morning, Benzinga reports. Benchmark currently has a $5.00 price objective on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Clene in a research note on Wednesday, […]

Related Keywords

, Silverarc Capital Management , Nasdaq , Clene Inc , Securities Exchange Commission , Clene Company Profile , Free Report , Get Free Report , Capital Management , Multiple Sclerosis , Clene Daily ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.